BioSpace News Archive

New data is from programs in B-cell non-Hodgkin lymphoma, multiple myeloma and paroxysmal nocturnal hemoglobinuria

New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients

Company’s Antibody Recruiting Molecules (ARMs) Demonstrated Strong Anti-Multiple Myeloma Activity In Multiple In Vivo Animal Models and Ex Vivo Against Patient Tumor Cells

Survival Data at Three Years in ZUMA-1 and Results from Study Cohort Evaluating Safety and Efficacy of Earlier Steroid Use with Yescarta® (axicabtagene ciloleucel) in Large B-cell Lymphoma to be Presented

Data to be presented next month at the American Society of Hematology Annual Meeting

Xencor, Inc. announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®13676, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies will be presented in a poster session during the 61st American Society of Hematology Annual Meeting in Orlando, Florida on Monday, December 9, 2019.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, announced that an abstract related to the Company’s lead drug candidate, tipifarnib, has been accepted for oral presentation at the upcoming American Society of Hematology Annual Meeting, which will be held from December 7-10, 2019 in Orlando.

Ultivue, a leading developer of tissue biomarker identification and quantification assays for translational research and pathology labs, today announced the expansion of its UltiMapper™ multiplex immunofluorescence kit portfolio with a T-reg and MDSC kit.

E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute and the University of Rochester.

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company’s ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will be presented at the 2019 American Society of Hematology (ASH) Annual Meeting, December 7-10, 2019, in Orlando, Fla.